SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company fou ...

Core Insights - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] - The company will present at the H.C. Wainwright Liver Disease Conference on October 21-22, 2025 [1] - A webcast of the presentation will be available on Aligos' website, with a replay accessible for at least 30 days [2] Company Overview - Aligos Therapeutics aims to improve patient outcomes through best-in-class therapies targeting high unmet medical needs, including chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] - The company utilizes a science-driven approach and extensive R&D expertise to advance its therapeutic pipeline [3]

Core Insights - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] Group 1: Company Overview - Aligos Therapeutics aims to improve patient outcomes through best-in-class therapies targeting high unmet medical needs such as chronic hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] - The company will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] Group 2: Presentation Details - A webcast of the presentation will be available on Aligos' website, with a replay accessible for at least 30 days following the event [2]

SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best- in-class therapies for liver and viral diseases, today announced that it will report the Company's second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company fo ...

Core Points - Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] - The company will present at the Jefferies Global Healthcare Conference on June 5, 2025 [1] - A live webcast of the presentation will be available on Aligos' website, with a replay accessible for at least 30 days [2] Company Overview - Aligos Therapeutics aims to improve patient outcomes through best-in-class therapies targeting high unmet medical needs such as chronic hepatitis B virus infection and metabolic dysfunction-associated steatohepatitis (MASH) [3] - The company utilizes a science-driven approach and has deep R&D expertise to advance its therapeutic pipeline [3]